Saposin-A derived peptides and uses thereof
AssigneeChildren's Medical Center Corporation
InventorRandolph S. Watnick
Life of this patent
Estimating the term…
Abstract
Disclosed herein are polypeptides and fusion polypeptides that have anti-angiogenic activity that can be used to inhibit tumor growth and tumor metastasis. The polypeptide consists of 9 or less consecutive amino acid residues (e.g., 8, 7, 6, 5, or 4) comprising the active core amino acid sequence DWLP, or an amino acid substitution variant thereof. Specific amino acid substitutions are disclosed herein. In some embodiments, the peptide consists essentially of 4-6 mers identified as exhibiting the activity of prosaposin A. Also disclosed herein are therapeutic compositions comprising the polypeptides and fusion polypeptides, and their use in the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
Claims6
An isolated peptide consisting of an amino acid sequence selected from the group consisting of CDWLPK (SEQ ID NO:
- 3) and DWLPK (SEQ ID NO:
- 4), wherein the peptide is acylated, carboxyamidated, pegylated, or conjugated to a polymer that enhances serum half-life of the peptide.
Dependencies are inferred from the claim text.